新辅助化疗后腋窝转阴且仅行前哨淋巴结活检的初始淋巴结阳性乳腺癌患者长期生存:荟萃分析
该荟萃分析纳入7项研究共915例新辅助化疗后前哨淋巴结活检阴性的初始淋巴结阳性乳腺癌患者,评估其仅行前哨淋巴结活检而不行腋窝淋巴结清扫的5年无病生存和总生存。汇总5年无病生存率为86%(95%CI 82.1-90.3),总生存率为93.1%(95%CI 87.8-97.0)。前哨淋巴结阳性且行腋窝淋巴结清扫者无病生存显著降低(OR 0.49,95%CI 0.35-0.69;P<0.001)。
要点
- 初始淋巴结阳性乳腺癌患者新辅助化疗后腋窝临床/影像学完全缓解且前哨淋巴结阴性,仅行前哨淋巴结活检的5年无病生存率为86%。
- 该组患者5年总生存率为93.1%。
- 前哨淋巴结阳性且行腋窝淋巴结清扫者无病生存显著低于前哨淋巴结阴性者。
核心结论
- 初始淋巴结阳性乳腺癌患者新辅助化疗后达到腋窝临床/影像学完全缓解且前哨淋巴结阴性,仅行前哨淋巴结活检而不行腋窝淋巴结清扫,5年无病生存率和总生存率均较高。
- 前哨淋巴结阳性且行腋窝淋巴结清扫者无病生存显著降低,残留病变者可能仍需进一步腋窝治疗。
研究设计与样本
- 遵循PRISMA指南的系统文献检索与荟萃分析,纳入7项研究共915例新辅助化疗后前哨淋巴结活检阴性的初始淋巴结阳性乳腺癌患者。
- 采用Der Simonian-Laird法和Cochran-Mantel-Haenszel法计算加权汇总估计值,比较仅行前哨淋巴结活检者与行腋窝淋巴结清扫者的生存。
主要发现
- 新辅助化疗后前哨淋巴结阴性患者汇总5年无病生存率为86%(95%CI 82.1-90.3),总生存率为93.1%(95%CI 87.8-97.0)。
- 前哨淋巴结阳性且行腋窝淋巴结清扫者较前哨淋巴结阴性者5年无病生存降低(OR 0.49,95%CI 0.35-0.69;P<0.001)。
- 前哨淋巴结阳性且行腋窝淋巴结清扫者较前哨淋巴结阴性者5年总生存无显著差异(OR 0.41,95%CI 0.16-1.02;P=0.06)。
- 仅行前哨淋巴结活检者与腋窝淋巴结清扫后病理完全缓解者无病生存无差异(OR 1.65,95%CI 0.71-3.79;P=0.24)。
临床怎么用
- 对初始淋巴结阳性、新辅助化疗后腋窝临床/影像学转阴且前哨淋巴结活检阴性的乳腺癌患者,可考虑豁免腋窝淋巴结清扫。
- 前哨淋巴结活检阳性提示残留病变者无病生存较差,应个体化考虑进一步腋窝治疗。
局限性
- 纳入研究数量较少(7项),样本量有限(915例),可能影响结论稳健性。
- 前哨淋巴结阳性且行腋窝淋巴结清扫者总生存比较的P值为0.06,差异未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NACT) in patients with breast cancer who are initially node-positive but convert to clinically/radiologically node-negative remains controversial. The primary aim was to assess pooled 5-year disease-free (DFS) and overall (OS) survival for patients who are initially node-positive but have a negative SLNB after NACT, and do not proceed to axillary lymph node dissection (ALND). METHODS: The study was performed using PRISMA guidelines. A systematic literature search of relevant databases was conducted. The Der Simonian-Laird and Cochran-Mantel-Haenszel methods were used to calculate weighted pooled estimates for OS and DFS for this group compared with patients who had NACT and proceeded to ALND after a negative or positive SLNB. RESULTS: Seven studies involving 915 patients who had a negative SLNB after NACT were included. Pooled estimates of 5-year DFS and OS in patients with a negative SLNB after NACT were 86 (95 per cent c.i. 82.1 to 90.3) and 93.1 (87.8 to 97.0) per cent respectively. Patients with a positive SLNB who underwent ALND had reduced 5-year DFS (OR 0.49, 95 per cent c.i. 0.35 to 0.69; P < 0.001) and OS (OR 0.41, 0.16 to 1.02; P = 0.06) compared with those who had a negative SLNB after NACT. There were no differences in DFS for patients who had a negative SLNB only compared with those undergoing ALND with a pCR (OR 1.65, 0.71 to 3.79; P = 0.24). CONCLUSION: Patients who are initially node-positive and who achieve a complete clinical/radiological axillary response after NACT with a subsequent negative SLNB have high rates of DFS and OS after 5 years. Patients with residual disease have significantly reduced DFS and further axillary treatment may still be warranted.
引用
- Keelan S, Boland MR, Ryan ÉJ, et al. Long-term survival in patients with node-positive breast cancer who undergo sentinel lymph node biopsy alone after neoadjuvant chemotherapy: meta-analysis. Br J Surg. 2023. PMID: 36512473. doi:10.1093/bjs/znac413
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。